Tomuzotuximab Completed Phase 1 Trials for Solid Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01222637CetuGEX™: Phase 1 Study in Cancer Patients